Enovis Corporation (ENOV)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Enovis Corporation beat consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 6 based on preliminary results, as adjusted EPS of $0.90 topped the $0.85 estimate by 6.3% and revenue of about $582.8 million edged the $581.8 million consensus by 0.2%. Revenue rose about 3% from about $564.5 million a year ago, while gross margin held near 62% and operating margin was about 3% as operating income came in around $17.4 million. Adjusted EPS was up about 14% from $0.79 a year ago, and the company generated operating cash flow of $75.0 million. Consensus for the next period calls for adjusted EPS of $0.85 on revenue of $562.1 million.
About Enovis Corporation
Enovis Corporation is a medical device company listed on the NYSE as ENOV that develops and sells orthopedic, rehabilitation, and reconstructive products worldwide. Under the DJO brand, it generated $2.2 billion of revenue in FY2025 from a portfolio that spans bracing, therapy, and implantable joint-reconstruction products.
Today's Snapshot
ENOV is trading 1.9% lower at 18.67, while its sector was flat. So far today, ENOV is within 1.2% of its 52-week low of 18.44.
Trading Volume
Below 10d avg (1.9M)
564K
vs S&P 500 Today
Underperforming Market
-1.33%
Updated: September 10, 2026 at 16:33 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$20.78 - $25.68Sell
- RSI (14)30.47Neutral
- Stochastic %K (14, 3, 3)8.64Buy
- MACD Level (12, 26)-1.94Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.